v3.26.1
Consolidated Statements of Comprehensive Loss (Income) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]    
Revenues $ 1,035 $ 530
Cost of revenues 1,928 6,255
Gross loss (893) (5,725)
Cost of development services and research and development expenses 9,622 10,623
Amortization of intangible assets 728 721
Change in Contingent consideration (4,643)
Selling, general and administrative expenses included credit losses of $2,724 for the year ended December 31, 2024 and ($24,367 for the year ended December 31, 2023) 14,822 35,134
Share in net loss of associated companies 8 734
Impairment of investment 699
Impairment of long-lived assets 18,338
Operating loss 39,768 53,636
Loss (profit) from deconsolidation of OBI, Korea, Belgium, Services and Octomera (see note 3 and note 20) (4,480) 5,343
Other income, net (606) (4)
Loss from extinguishment in connection with loans 5,422 283
Credit loss on convertible loan receivable 2,688
Financial expenses, net 4,508 2,499
Inducement expense on conversion of convertible loans 4,304
Loss before income taxes 48,916 64,445
Tax expense 97 473
Net loss 49,013 64,918
Net (loss) income attributable to non-controlling interests (848) (9,557)
Net loss attributable to Orgenesis Inc. $ 48,165 $ 55,361
Loss per share:    
Basic $ 11.44 $ 19.08
Diluted $ 11.44 $ 19.08
Weighted average number of shares used in computation of Basic and Diluted loss per share:    
Basic 4,210,839 2,900,787
Diluted 4,210,839 2,900,787
Comprehensive loss:    
Other Comprehensive loss – Translation adjustment $ (853) $ 49
Release of translation adjustment due to deconsolidation of Orgenesis Korea and the Belgian Subsidiary in 2024 (Octomera in 2023) 534 (384)
Comprehensive loss 48,694 64,583
Comprehensive (loss) income attributed to non-controlling interests (848) (9,557)
Comprehensive loss attributed to Orgenesis Inc. $ 47,846 $ 55,026